Wednesday, July 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Fauci and WHO Director-General disagree on COVID booster programs

As the omicron variant surges throughout the United States, health officials are urging Americans to get their Covid booster vaccines when eligible. However, during press briefings last week, America’s top infectious disease specialist, Dr. Anthony Fauci, and the World Health Organization (Who) Director-General Dr. Tedros Adhanom Ghebreyesus do not appear to see eye to eye when it comes to booster vaccination programs during the fight against Covid.

“No country can boost its way out of the pandemic,” Dr. Tedros Adhanom Ghebreyesus said during a briefing.

The WHO Director-General criticized blanket COVID-19 booster programs that are being rolled out while other countries struggle to get vaccine supplies. Ghebreyesus said in the briefing that only half of WHO’s Member States have met the target of vaccinating 40 percent of their populations by the end of the year because of unequal distribution of global supply.

Source: Fox News

https://www.foxnews.com/health/fauci-who-director-general-disagree-covid-booster-programs

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!